	US 11,890,337 B2
	VLP-based bivalent ebola vaccines and methods of making and using same
Karnail Singh, Deerfield Township, OH (US); and Paul Spearman, Cincinnati, OH (US)
Assigned to Children's Hospital Medical Center, Cincinnati, OH (US)
Filed by Children's Hospital Medical Center, Cincinnati, OH (US)
Filed on Aug. 25, 2021, as Appl. No. 17/411,097.
Application 17/411,097 is a division of application No. 16/494,841, granted, now 11,129,886, previously published as PCT/US2018/024747, filed on Mar. 28, 2018.
Claims priority of provisional application 62/477,480, filed on Mar. 28, 2017.
Prior Publication US 2021/0386849 A1, Dec. 16, 2021
Int. Cl. A61K 39/12 (2006.01); A61K 39/00 (2006.01); C12N 7/00 (2006.01); A61P 37/02 (2006.01); C07K 14/08 (2006.01)

CPC A61K 39/12 (2013.01) [C07K 14/08 (2013.01); C12N 7/00 (2013.01); A61K 2039/5258 (2013.01); C12N 2740/10023 (2013.01); C12N 2740/11023 (2013.01); C12N 2740/12023 (2013.01); C12N 2740/13023 (2013.01); C12N 2740/14023 (2013.01); C12N 2740/15023 (2013.01); C12N 2740/16022 (2013.01); C12N 2740/16023 (2013.01); C12N 2760/14123 (2013.01); C12N 2760/14134 (2013.01)]

8 Claims

1. A method for protecting an individual in need thereof against an Ebola virus species selected from Zaire (EBOV), Sudan (SUDV), Bundibugyo (BDBV), Tai Forest (TAFV), and combinations thereof, comprising administering a virus-like particle (VLP)-based bivalent vaccine composition comprising a spherical retroviral Group-specific Antigen (“Gag”) protein core and at least two species of Ebola glycoproteins; wherein said at least two species of Ebola glycoproteins are incorporated into a surface of a spherical Gag core;

wherein said VLP-based bivalent vaccine presents at least two species of Ebola glycoprotein antigens; and

wherein said spherical Gag protein core has a diameter of from about 100 to about 300 nanometers.